Confident in the promising future of bio industry, Hugel (founded in 2001) is a biopharmaceutical company that has established a global-level R&D infrastructure. Hugel has grown progressively in medical aesthetics with high quality products like ‘Botulax’ and ‘The Chaeum (Dermalax)’. Starting in 2015, the company has expanded its business portfolio to include medical therapeutics products. Hugel has already established itself as a leader in the Korean bio industry and continues to seek out future business opportunities. These efforts have allowed Hugel to achieve record quarterly revenue of 50bn KRW in 4Q17 and record annual revenue in 2017. Hugel currently markets its products in 32 countries and is in the process of expanding its global footprint to more than 40 countries. Hugel is opening a new chapter, making a transformation from a Korean company to a global biopharmaceutical company.